亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study

医学 内科学 胃肠病学 肝细胞癌 不利影响 索拉非尼 中止 肿瘤科
作者
Tao Ning,Danyang Li,Ting Deng,Yuxian Bai,Ye Chen,Zhiyu Wang,Bin Hu,Yi Ba,Wei Lu
出处
期刊:Cancer [Wiley]
卷期号:130 (18): 3137-3146 被引量:9
标识
DOI:10.1002/cncr.35377
摘要

Abstract Background Effective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretically, a combination of tyrosine kinase inhibitors (TKIs) with ICIs may restore immunotherapy sensitivity. Methods In this phase 1b study, patients received AL2846, an antiangiogenic TKI with multiple targets (c‐MET, VEGFR1, c‐KIT, Axl, RET, KDR, and VEGFR3), in combination with an anti–PD‐L1 antibody (TQB2450) until disease progression, intolerable toxicity, death, or discontinuation for any cause. The primary end points included overall response rate (ORR) and safety, with secondary end points encompassing progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response. Results Between November 2021 and September 2022, 18 patients with ESCC and 15 patients with HCC, whose ORR was 11.1% (95% confidence interval [CI], 3.1%–32.8%) and 0%, respectively, were enrolled. Adverse events (AEs) of any grade and treatment‐related AEs were documented in 32 patients (97.0%) and 31 patients (93.9%), respectively. Grade 3 or higher AEs were observed in 10 patients (30.3%), with vomiting (6.1%) and infectious pneumonia (9.1%) being the most prevalent. Median PFS and OS values were 3.22 months (95% CI, 1.35–5.68 months) and 5.98 months (95% CI, 3.71–8.87 months), respectively, in patients with ESCC, and 5.55 months (95% CI, 2.66 months to not evaluable [NE]) and 16.72 months (95% CI, 4.86 months to NE), respectively, in patients with HCC. The DCRs were 66.7% (95% CI, 43.75%–83.72%) in patients with ESCC and 73.3% (95% CI, 48.05%–89.10%) in patients with HCC. Conclusions Combined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy‐refractory patients with advanced ESCC and HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
柯擎汉完成签到,获得积分10
1秒前
2秒前
佳佳发布了新的文献求助10
3秒前
帅气逼人发布了新的文献求助10
7秒前
11秒前
田様的应助被kali采纳,获得10
11秒前
11秒前
Hayat的应助被科研通管家采纳,获得30
11秒前
大只佬的应助被科研通管家采纳,获得10
11秒前
斯文败类的应助被佳佳采纳,获得10
17秒前
20秒前
23秒前
悦耳向松完成签到,获得积分10
24秒前
zhiwei发布了新的文献求助10
24秒前
26秒前
cjhsci发布了新的文献求助10
27秒前
29秒前
萧雨墨发布了新的文献求助10
34秒前
九星完成签到 ,获得积分10
37秒前
慕青的应助被yao采纳,获得10
39秒前
41秒前
43秒前
45秒前
47秒前
49秒前
萧雨墨发布了新的文献求助10
51秒前
LuXiaoyu的应助被Mooncloud采纳,获得10
57秒前
丘比特的应助被的速度采纳,获得10
57秒前
59秒前
1分钟前
自觉的河马关注了科研通微信公众号
1分钟前
1分钟前
华仔的应助被拉长的远侵采纳,获得10
1分钟前
xinjiu发布了新的文献求助10
1分钟前
1分钟前
刘刘完成签到 ,获得积分10
1分钟前
1分钟前
jianglan完成签到,获得积分10
1分钟前
zhiwei发布了新的文献求助10
1分钟前
汉堡包的应助被胡图图采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577194
关于积分的说明 21851931
捐赠科研通 7788156
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792